Efficacy and safety of Boceprevir triple therapy in previously treated patients with HCV Genotype 1 (G1) infection in German real-life
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, P Geyer, B Weber, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2015 · Heft 12
Bibliografische Angaben
Zusammenfassung
Background: Since 2011, triple therapy with the HCV protease inhibitor boceprevir (BOC) is widely used as standard of care for patients (pts) with chronic HCV G1 infection. The present interim analysis of the NOVUS observational study investigated the efficacy and safety of BOC triple therapy in pretreated patients in German real-world according to the previous virologic response to dual therapy with pegylated interferons (PegIFN) and ribavirin (RBV). Methods: From April 2012 until January 2014, 536 pts with G1 infection were recruited in the ongoing NOVUS study by 97 practices and hospitals in Germany. Pts were…
